**Supporting Information**

Figure S1. Risk of bias graph of each included study.

The assessments regarding each risk of bias item are presented across all the included studies.

Figure s1.eps

Figure S2. Traditional meta-analysis for comparisons of PFS among regimens.

The forest plot shows a traditional meta-analysis for PFS results. The results were not pooled because of the various types of intervention and control regimens.

tmetaFigure S2.eps

Figure S3. Traditional meta-analysis for comparisons of OS among regimens.

The forest plot shows a traditional meta-analysis for OS results. The results were not pooled because of the various types of intervention and control regimens.

Figure S3.eps

Table S1. The league table for ORR in all TNBC patients estimates therapeutic strategies according to their relative effects, logOR (95% credible intervals).

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| B1C1# |  |  |  |  |  |  |  |  |  |  |  |
| -0.75 (-3.97,2.47) | PT2 |  |  |  |  |  |  |  |  |  |  |
| -1.20 (-3.73,1.33) | -0.45 (-2.45,1.55) | P |  |  |  |  |  |  |  |  |  |
| -0.23 (-2.83,2.37) | 0.52 (-2.71,3.76) | 0.97 (-1.57,3.51) | OP |  |  |  |  |  |  |  |  |
| -1.14 (-4.28,2.01) | -0.38 (-3.12,2.35) | 0.06 (-1.80,1.93) | -0.91 (-4.06,2.25) | I1P |  |  |  |  |  |  |  |
| -0.89 (-3.76,1.99) | -0.13 (-3.12,2.85) | 0.31 (-1.90,2.53) | -0.66 (-3.54,2.23) | 0.25 (-2.65,3.15) | E2P |  |  |  |  |  |  |
| -1.75 (-4.93,1.44) | -1.00 (-3.78,1.79) | -0.55 (-2.49,1.39) | -1.52 (-4.72,1.68) | -0.61 (-3.31,2.08) | -0.86 (-3.81,2.08) | E1P |  |  |  |  |  |
| -0.83 (-4.03,2.38) | -0.08 (-2.88,2.73) | 0.37 (-1.60,2.34) | -0.60 (-3.81,2.62) | 0.31 (-2.40,3.02) | 0.06 (-2.90,3.02) | 0.92 (-0.94,2.79) | E1 |  |  |  |  |
| -1.52 (-4.05,1.00) | -0.77 (-3.42,1.88) | -0.32 (-2.06,1.42) | -1.29 (-3.83,1.25) | -0.39 (-2.94,2.17) | -0.64 (-2.00,0.73) | 0.23 (-2.38,2.84) | -0.69 (-3.32,1.93) | C2P |  |  |  |
| -1.39 (-3.22,0.44) | -0.64 (-3.29,2.01) | -0.19 (-1.94,1.55) | -1.16 (-3.01,0.69) | -0.26 (-2.81,2.30) | -0.51 (-2.72,1.71) | 0.36 (-2.25,2.97) | -0.56 (-3.19,2.07) | 0.13 (-1.61,1.87) | B1P |  |  |
| -0.89 (-3.48,1.71) | -0.14 (-3.37,3.09) | 0.31 (-2.22,2.85) | -0.66 (-2.52,1.20) | 0.25 (-2.90,3.40) | -0.00 (-2.88,2.88) | 0.86 (-2.33,4.05) | -0.06 (-3.27,3.15) | 0.63 (-1.90,3.17) | 0.50 (-1.34,2.34) | B1OP |  |
| -1.94 (-4.46,0.59) | -1.19 (-3.84,1.47) | -0.74 (-2.48,1.00) | -1.71 (-4.25,0.83) | -0.80 (-3.36,1.75) | -1.05 (-3.26,1.16) | -0.19 (-2.80,2.42) | -1.11 (-3.74,1.52) | -0.42 (-2.16,1.32) | -0.55 (-2.29,1.19) | -1.05 (-3.58,1.48) | B1C2P |

#: B1: Bevacizumab; C1: Capecitabine; C2: Carboplatin; E1: EndoTAG-1; E2: Epirubicin; I1: Iniparib; O: Onartuzumab; P: Paclitaxel; T2: Tigatuzumab.

Table S2. The league table for ORR in TNBC patients without metastasis estimates therapeutic strategies according to their relative effects, logOR (95% credible intervals).

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| B1C2P |  |  |  |  |  |
| 0.74 (-1.01,2.48) | P |  |  |  |  |
| 0.80 (-1.75,3.36) | 0.06 (-1.80,1.93) | I1P |  |  |  |
| 1.05 (-1.16,3.27) | 0.31 (-1.90,2.53) | 0.25 (-2.65,3.15) | E2P |  |  |
| 0.42 (-1.32,2.16) | -0.32 (-2.07,1.42) | -0.39 (-2.94,2.17) | -0.64 (-2.00,0.73) | C2P |  |
| 0.55 (-1.20,2.29) | -0.19 (-1.94,1.56) | -0.25 (-2.81,2.30) | -0.50 (-2.72,1.71) | 0.13 (-1.61,1.88) | B1P |

#: B1: Bevacizumab; C2: Carboplatin; E2: Epirubicin; I1: Iniparib; P: Paclitaxel.